Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors from the central nervous technique, conolidine modulates alternate molecular targets. A Science Advances study observed that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://douglasq319lan3.blog-gold.com/profile